Company continues to advance its novel octreotide capsules candidate through Phase 3 clinical trials in the U.S. and E.U.
WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today recognizes November 1st as Acromegaly Awareness Day.
“Today, we acknowledge the acromegaly patients, their families and advocates, as well as the clinical thought leaders who have been instrumental in our efforts to develop an oral treatment alternative for this rare but serious disease,” said Mark Fitzpatrick, President and Chief Executive Officer of Chiasma. “We would also like to thank the Acromegaly Community for the critical support that they provide to acromegaly patients, and their ongoing efforts to elevate awareness of the need for better maintenance treatment options.”
“On Acromegaly Awareness Day, we strive to raise the profile of this rare disease. Additionally, we are able to recognize the efforts of companies like Chiasma who are working to improve the lives of people living with acromegaly,” said Jill Sisco, President of the Acromegaly Community.
Chiasma recently announced that it had completed enrollment in its ongoing Phase 3 CHIASMA OPTIMAL (Octreotide capsules vs. Placebo Treatment In MultinationAL centers) clinical trial of its octreotide capsules product candidate, conditionally trade-named MYCAPSSA®, for the maintenance treatment of adults with acromegaly. Chiasma exceeded its target enrollment of 50 patients in the trial with a total of 56 acromegaly patients randomized in 17 countries worldwide, including 21 patients from the U.S. The Company expects topline data from this study by September 2019. In addition, the Company is advancing its octreotide capsules candidate through a second Phase 3 clinical trial, MPOWERED™ (Maintenance of Acromegaly Patients with Octreotide Capsules Compared With Injections – Evaluation of REsponse Durability), under a protocol accepted by the European Medicines Agency (EMA).
Chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In September 2017, the Company initiated CHIASMA OPTIMAL, its third Phase 3 clinical trial for its octreotide capsules product candidate, conditionally trade-named MYCAPSSA®, for the maintenance therapy of adult patients with acromegaly in whom prior treatment with somatostatin analogs has been shown to be effective and tolerated following agreement with the FDA on the design of the trial through a special protocol assessment. Chiasma is headquartered in Waltham, MA with a wholly-owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the Company’s website at www.chiasma.com.
Ashley R. Robinson
LifeSci Advisors, LLC